---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-017461"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:11:40.816848+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q4 GSK royalties $66M, IST sales up 47% YoY; ZEVTERA launch mid-2025

## Summary
- Q4 GSK royalties $66.0M; full year $255.6M vs $252.7M in 2023.
- U.S. net product sales $24.9M in Q4, full year $80.9M (+47% YoY).
- Acquired U.S. rights to ZEVTERA; launch expected mid-2025.
- Zoliflodacin NDA submission to FDA on track for early 2025.
- Cash and receivables $391.4M; net income $20.3M in Q4 ($0.32 EPS).

## SEC filing metadata
- accession: 0001104659-25-017461
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/0001104659-25-017461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/tm257428d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-017461
- JSON: https://secwatch.observer/filing/0001104659-25-017461.json
- Plain text: https://secwatch.observer/filing/0001104659-25-017461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.